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ORIGINAL

ARTICLE

Gaps and recommendations for clinical
management of truncal acne from the
Personalising Acne: Consensus of
Experts panel
Jerry Tan, MD,a,b Andrew Alexis, MD, MPH,c Hilary Baldwin, MD,d,e Stefan Beissert, MD,f
Vincenzo Bettoli, MD,g James Del Rosso, DO,h,i Brigitte Dreno, MD, PhD,j Linda Stein Gold, MD,k
Julie Harper, MD,l Charles Lynde, MD,m,n Diane Thiboutot, MD,o
Jonathan Weiss, MD,p and Alison M. Layton, MB ChBq,r
Windsor and Markham, Ontario, Canada; New York and Brooklyn, New York; New Brunswick, New
Jersey; Dresden, Germany; Ferrara, Italy; Las Vegas, Nevada; Nantes, France; Detroit, Michigan;
Birmingham, Alabama; Hershey, Philadelphia; Snellville, Georgia; and York and
Harrogate, United Kingdom
Background: Truncal acne is common and burdensome for patients; however, there is paucity of evidence
and guidance for the management of truncal acne. Currently, clinical practice guidelines provide very little
guidance on the assessment or management of truncal acne.
Objectives: To identify unmet needs in truncal acne and make recommendations to address clinical and
management gaps using an international consensus.
Methods: The Personalising Acne: Consensus of Experts panel consisted of 13 dermatologists, who used a
modified Delphi approach to reach a consensus on statements related to clinically relevant aspects of
truncal acne evaluation and management. A consensus was defined as $75% of the panelists voting
‘‘agree’’ or ‘‘strongly agree.’’ The voting was electronic and blinded.
Results: The panel identified gaps and made recommendations related to truncal acne identification,
assessment, and grading; the evaluation of the impact on patients; and treatment goals and factors to be
considered for its management.
Limitations: The recommendations are based on expert opinion, in the absence of high-quality evidence.
Conclusions: We highlighted addressing not just facial acne but also truncal acne during patient
consultations. The recommendations made herein may help facilitate the care of patients who present with
truncal acne, with or without facial acne. ( JAAD Int 2021;5:33-40.)
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INTRODUCTION

Two chairpersons from the
CAPSULE SUMMARY
Acne vulgaris is estimain panel oversaw the
mated to affect 9.4% of the
process and were involved
global population (for all
in panel selection and
Truncal acne is common and
ages). Nearly three-quarters
Delphi design. The panelburdensome for patients; however,
(73%) of adults (over
ists were selected based
published evidence and guidance for its
20 years of age) report
on their expertise in acne
clinical management are lacking.
ever having acne,1-3 with
and their reach in North
We provide recommendations for
as many as 61% presenting
America and Europe.
relevant clinical factors to be considered
with truncal involvement.4-8
when managing patients with truncal
The latter is inclusive of the
Modified Delphi process
acne, to improve comprehensive patient
shoulders, chest, and back.9
A modified Delphi procare.
Despite the high prevalence
cess, consisting of a series of
of truncal acne, there is
5 e-surveys and an interim
paucity of data on its clingroup webinar between the
ical aspects, including management options. The
third and fourth e-survey, was used (Fig 1). An initial
treatment of truncal acne has not been rigorously
literature search was conducted to identify gaps in
studied in clinical trials, with only 1 publication
the clinical management of acne and the need to
reporting the results of 2 identical vehiclemake recommendations that incorporate all precontrolled randomized clinical trials in patients
sentations of acne. The search process, which is
with moderate facial and truncal acne.10
outlined in detail in Supplemental Material (available
Furthermore, limited information is provided by
via Mendeley at https://data.mendeley.com/
clinical guidelines about its assessment and
datasets/cnffzf3j4v/2), included an audit of acne
grading, factors to be considered during discusclinical guidelines for Europe, the United States, and
sions with patients, and its treatment.11-13 This lack
Canada11-13 to identify research gaps, followed by an
of evidence and guidance, coupled with the fact
additional literature assessment of the relevant literthat many patients do not voluntarily report their
ature to address key clinical management questions
truncal acne, is likely to result in undertreatment
associated with the gaps identified in the audit. The
and unresolved disease-related burdens.4
searches were performed using the PubMed Central
With acne well-established as a condition with
and Cochrane databases and limited to a period from
adverse psychosocial impact,14,15 there is a need
January 2016 to present; the searches included only
to address and manage the whole spectrum of
English-language articles. For the truncal acne manacne presentations, including that on the trunk.
agement questions, the search terms included the
Indeed, truncal acne represents an additional
word ‘‘acne’’ in combination with the following
burden for patients beyond that caused by facial
words: trunk, truncal, and treatment. Articles were
acne alone, with specific and distinct effects on
excluded if they were on non-human animals,
activities of daily living, self-esteem and, social
in vitro or ex vivo studies, or did not contribute to
activities.14,16 As part of a 2020 consensus projthe research questions. A total of 36 articles specific
ect, the Personalising Acne: Consensus of
to truncal acne were retrieved at the end of the
Experts (PACE) panel aimed to identify unmet
search, and after applying predefined exclusions, 11
needs in truncal acne and use an expert
were used to address the research questions relating
consensus, combined with the best available
to truncal acne (Supplemental Material). The quality
evidence, to make recommendations pertaining
of evidence was rated using the grading of recomto gaps in truncal acne diagnosis, classification,
mendations assessment, development and evaluaand management.
tion (GRADE) methodology17 and used to guide the
e-survey content. Two independent raters (Mr
Pickford and Dr Harris) performed a separate grade
METHODS
classification of the evidence, with discrepancies
Expert panel
resolved by a third rater (Dr Hughes) with experiThe expert panel consisted of 13 dermatoloence in the use of the grading of recommendations
gists, from Canada (n = 2), France (n = 1),
assessment, development and evaluation methodolGermany (n = 1), Italy (n = 1), the United
ogy. The final results were approved by the cochairs.
Kingdom (n = 1), and the United States (n = 7).
d

d
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Abbreviations used:
PACE:
PGA:

Personalising Acne: Consensus of Experts
physicians’ global assessment

E-survey development and administration
Consensus statements were structured to assess
the level of agreement using the following response
range: ‘‘strongly disagree,’’ ‘‘disagree,’’ ‘‘agree,’’
‘‘strongly agree,’’ or ‘‘unable to answer.’’ A consensus
was defined as $75% of the panelists voting ‘‘agree’’
or ‘‘strongly agree.’’ Some questions were posed as
multiple-choice questions for which several responses could be selected; the results of these
questions were presented as a consensus when
chosen by $75% of the panelists. Some questions
were open ended to allow for the development of
consensus statements in a subsequent round of
voting. A virtual interim meeting was held after the
third e-survey to review topics covered to date and
discuss potential areas to explore in the subsequent
surveys. The e-surveys were programmed and
administered, and the responses were collated by
Ogilvy Health UK in order to maintain blinding.
Truncal acne was 1 of 4 major topics explored in the
e-surveys and virtual interim meeting and will be the
focus of this current manuscript. Acne sequelae,
longitudinal management, and patient types were
also covered and will be reported in subsequent
publications.

RESULTS
Definition of consensus recommendations
The result of the consensus statement voting is
given in parentheses (eg, 12/13 voted ‘‘agree’’ or
‘‘strongly agree’’). All 13 experts completed all 5
surveys. Some panel members occasionally voted
‘‘unable to answer’’; these votes were not included in
the denominator. The full statements are available in
Supplemental Material. The elements that were
considered but not voted on are included in the
‘‘Discussion points’’ section below.
Baseline demographics
All 13 dermatologists included in the PACE panel
manage patients with truncal acne. For a majority of
them (85% [n = 11]), #25% of their patients present
with truncal acne alone. Just under half of the
panelists (46% [n = 6]) indicated that 26%-50% of
their patients present with combined facial and
truncal acne. The other 7 (54%) panelists approximated that 51%-75% of their patients have combined
facial and truncal acne.

When asked whether the panel considered clinical practice guidelines useful for the evaluation and
management of acne in different anatomic locations,
69% (n = 9) and 62% (n = 8), respectively, did not find
them useful, and 8% (n = 1) and 15% (n = 2),
respectively, did find them useful.
Identifying patients with truncal acne
The gaps and recommendations for identifying
patients with truncal acne are provided in Table I.
Discussion points. It was discussed that it might
not be reluctance on a patient’s part per se to initiate
a conversation about their truncal acne but a desire
to prioritize a discussion of their facial acne instead.
However, there exists a cohort of patients who may
be too embarrassed to report or proactively show
acne on their trunk. Thus, it is important to proactively address this during consultations. The panelists reported that discussions about the management
of truncal acne are typically initiated by themselves
as the treating dermatologist (69% [n = 9]) rather than
the patient or their guardian (23% [n = 3]; 8% [n = 1]
selected ‘‘unable to answer’’).
Assessment and grading of truncal acne
The gaps and recommendations for the assessment and grading of truncal acne are provided in
Table II.
Discussion points. It was highlighted that the
severity of acne at different locations on the trunk
(eg, chest and back) should be assessed independently of each other because they can be distinctly
different. The panel reported using the following
scales or tools for grading truncal acne in current
clinical practice: investigator’s global assessment,
physician’s global assessment (PGA), Leeds visual
severity scale, Echelle de Cotation des Lesions
d’Acne grading, comprehensive acne severity scale,
and general mild, moderate, or severe categorization. It was discussed that most grading scales were
developed for use in clinical trials and are not
optimized for use in a clinical setting; in research,
conversely, it can be difficult to combine both
clinician- and patient-reported measures in 1 instrument that is also acceptable to regulatory authorities.
A simplified version of these tools, which takes into
account both the perspectives, may lend itself to use
in practice.
Impact of truncal acne on patients and
treatment goals
The gaps and recommendations for the impact of
truncal acne and treatment goals are provided in
Table III.
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Fig 1. The Personalising Acne: Consensus of Experts modified Delphi process.

Table I. Consensus gaps and a recommendation
for identifying patients with truncal acne
Gaps
d Not all patients report their truncal acne (13/13)
d During clinical visits, patients often prioritize discussing
their facial acne over discussing their truncal acne (12/13)
d It is common for patients to only report their truncal
acne if it is severe or particularly bothersome to them
(11/13)
d There is a need for guidance on factors to be consider
when discussing truncal acne with patients (11/11)*
Recommendation
d Prompting patients to discuss their truncal acne during
clinic visits can help identify those who might benefit
most from treatment (13/13)
*Two participants selected ‘‘unable to answer.’’

Table III. Consensus gaps and recommendations
for the impact of truncal acne and treatment goals
Gaps
d Truncal acne can have a specific impact on patients,
which is distinct from that of facial acne (13/13)
d The common concerns or issues reported by patients
specifically with regard to their truncal acne include the
following:
B Concerns about revealing skin in public (13/13)
B Concerns about wearing clothes that reveal skin (12/
13)
B Difficulties with applying topical treatments to the
back (11/13)
Recommendations
d Treatment goals should be personalized to the individual patient depending on the specific impact of acne in
certain regions (13/13)
d The specific burden of disease on an individual patient
should influence the choice of treatment (13/13)

Table II. Consensus gaps and recommendations
for the assessment and grading of truncal acne
Gaps
d There is a need for guidance on the assessment and
grading of truncal acne (13/13)
d There is a need for a standardized scale/tool to assess,
grade, and monitor the severity of truncal acne (13/13)
Recommendations
d The severity of truncal acne should always be assessed
independently of the severity of facial acne (13/13)
d The essential clinical components to be included in a
truncal acne grading tool or scale include body surface
area involvement, size of lesions, degree or extent of
inflammatory lesions, impact on patients quality of life,
and extent of scarring (12/13)
d A truncal acne grading scale or tool should be practical
and easy to use in the clinic (13/13)
d A new grading scale or tool to assess truncal acne
should be developed based on input from patients to
ensure that the elements that are important to them are
captured (11/13)

Discussion points. The panel considered truncal acne as a burden for all patients with truncal acne;
however, it was noted that the burden could vary
between patients. The visual analog scale (or similar)
was suggested as a useful tool to assess factors
related to the impact of the disease on patients and,
thus, help inform treatment goals.

Factors to be considered for the management
of truncal acne
The gaps and recommendations for considerations for the management of truncal acne are
provided in Table IV.
Discussion points. In the panel’s opinion, the
underlying pathophysiology of truncal acne is
similar to that of facial acne. Any differences in
response to treatment could be potentially attributed
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Table IV. Consensus gaps and recommendations
for factors to be considered for the management of
truncal acne
Gaps
d There is a need for guidance on factors to be considered
for the treatment and management of truncal acne (13/13)
d There is a need for further evidence to support treatment efficacy in truncal acne (13/13)
d There is a need for further evidence to support treatment safety in truncal acne (11/13)
d There is a need to improve vehicles used for topical
therapies for truncal acne (13/13)
d There is a need to improve application methods for
topical therapies for truncal acne (12/13)
Recommendations
d The treatment-related factors that should be considered
when selecting a treatment for truncal acne include the
following:
B Type of acne, eg, nodules (13/13)
B Efficacy of treatment (13/13)
B Safety profile of treatment (10/13)
B Practicality of applying topical treatment to the
back (12/13)
B Potential to bleach or stain clothing (10/13)
d

The patient-related factors that should be considered
when selecting a treatment for truncal acne include the
following:
B Body surface area affected (13/13)
B Previous treatment history (13/13)
B Patient preference (12/13)
B Location of truncal acne (ie, upper back, lower
back, chest, and shoulders; 10/13)

d

The truncal acne types that require additional considerations for their management or treatment include the
following:
B Truncal acne at high risk of scarring (13/13)
B Truncal acne with predominantly deep comedones
(not related to hidradenitis suppurativa; 11/13)
B Truncal acne associated with hidradenitis suppurativa (10/13)
B Truncal acne with predominantly open comedones
(10/13)

to the number and depth of sebaceous glands in
either area, the relative thickness of the dermis, the
role of exacerbating factors, and challenges related
to the application of topical therapies (ie, physical
application or when a patients runs out of a
medication supply before a refill can be given).
The examples of the treatments that panelists prescribe for truncal acne include topical benzoyl
peroxide, topical and systemic retinoids, oral antibiotics (with appropriate cautions in terms of resistance), and oral isotretinoin. Addressing the
inconvenience of application was highlighted as a

key consideration while prescribing a topical treatment for truncal acne. In addition, acne associated
with inflammatory bowel disease was also highlighted as requiring additional considerations for
management and treatment.
The panel noted that patients’ expectations of
truncal acne treatment should be managed in a way
similar to those of facial acne treatment, including
counseling regarding expected timeframes and the
importance of adherence to treatment. The panel
highlighted the importance of patients having a
realistic expectation of treatment efficacy and potential adverse events. It was acknowledged that patients might be willing to accept slower onset of
efficacy on the trunk than on the face, although more
data are needed to support this observation.
Furthermore, although clearance is ideal, significant
improvement may be an acceptable goal for many
patients. It was noted that patients may be more
willing to tolerate harsher or less cosmetically
elegant products on the trunk than on the face.
The panel recommended that truncal acne be
discussed with all patients with acne to identify those
who might benefit most from treatment. In addition,
it was noted that patients who already present with
truncal scarring are at high risk of future scarring.
Therefore, it is important to assess truncal acne
independently of facial acne to determine its specific
burden on individual patients and subsequently
adjust their management plan, align treatment goals,
and manage their expectations accordingly.

DISCUSSION
Truncal acne is a well-established condition that is
common and burdensome for patients.4-8,14-16 In a
recent cross-sectional online survey of 1309 patients
with either combined truncal and facial acne or facial
acne alone, the specific impact of acne was assessed
in these locations using validated quality-of-life
measures. Increasing severity of truncal acne was
reported to increase adverse impact on the quality of
life, irrespective of facial acne severity.16 This study
highlights the need for improvements in patient care
for truncal acne to lessen their burden. However,
because of the lack of clinical evidence of truncal
acne treatments and less mention in clinical practice
guidelines,8 the need to provide physicians with
practical advice on truncal acne management exists.
Indeed, the paucity of information available to
physicians about truncal acne may be reflected by
the low proportion of panel members consulting
them for guidance for the management of these
patients (however, this may also be attributed to their
clinical experience and knowledge). The PACE
panel aimed at rectifying this situation by identifying
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key research gaps and providing recommendations
for assessment and management beyond just treatment selection.
The panel confirmed that there is a gap in clinical
research regarding the evidence of the efficacy and
safety of truncal acne treatments. In the absence of
sufficient high-quality evidence or clinical guidelines,
the PACE panel identified various treatment- and
patient-related factors to guide truncal acne management. The use of topical and oral antibiotics should be
considered in light of the best evidence, including a
means to minimize antibiotic resistance.11-13 The
panel highlighted the need for better application
methods and vehicles for topical treatments. Patient
preference for vehicles for topical treatment is relevant to treatment adherence;18 with treatment adherence in patients with acne known to be an issue
(especially for those prescribed topical treatments)8
and a major reason for treatment failure,18-24 this is an
area that is critical to be explored further.
The PACE panel also identified the need for a
standardized truncal acne grading scale or tool and
identified several clinical components and features
that are essential to be incorporated. The clinical
guidelines do not advise on how to assess or grade
truncal acne, and in the absence of a ‘‘gold standard’’
for the assessment of acne,25,26 physicians and clinical
researchers may use simplified methods of ‘‘mild,’’
‘‘moderate,’’ and ‘‘severe’’ grading25 or methods that
focus on primary lesions (eg, comedones, papules,
and nodules) or signs of a secondary change (eg,
sequelae).26 Only a handful of the existing acne
grading scales are inclusive of truncal acne: the
Leeds system, global acne grading system, and
comprehensive acne severity scale.27-29 However,
none is exclusive to truncal acne.8 In addition, the
Leeds system is not validated and only considers
inflammatory lesions. Investigator’s global assessment
and PGA scores have been used in clinical studies of
truncal acne in patients presenting with acne on the
trunk and face,30-32 and in addition, the PGA was used
to assess efficacy in 2 recent registration studies that
resulted in Food and Drug Administration’s approval
of trifarotene,10 indicating the current Food and Drug
Administration endorsement of the PGA as an appropriate clinician-reported outcome measure for truncal
acne in clinical trials. The development of a standardized scale or tool for the assessment of truncal acne
was beyond the scope of this consensus and would
require a thorough development, evaluation, validation, and reliability-testing process. This represents an
area for future evaluation.
This project incorporated the opinions of a global
panel of dermatologists who achieved a consensus
using a modified Delphi process. The limitation of
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the latter is that it primarily relies on expert opinion,
necessary because of the absence of evidence.33-35
With current evidence of truncal acne limited across
the spectrum of management considerations (assessment, grading, treatment efficacy, safety, etc), this
method provides a systematic, egalitarian method to
develop consensus recommendations to improve
patient care.36 A particular strength of the Delphi
process is that the group size does not depend on
statistical power; instead, the group is selected for
expertise,37,38 with the number of panelists within
the recommended range of 10-18.37 The blinded
voting reduced the potential for bias in the Delphi
voting process.
An important limitation to be considered overall is
that the identified gaps and recommendations proposed by the panel reflect physicians’ perspectives
on patient concerns regarding truncal acne.
However, this could potentially differ from patients’
perspectives. In addition, this perspective was of a
group of expert dermatologists who are likely to see a
more severe spectrum of patients with acne and/or
those who are more burdened by it. The incorporation of the ‘‘patient voice’’ via direct patient involvement in the future updates of these recommendations
or clinical practice guidelines would be of value to
consider as an area of future work.

CONCLUSIONS
The gaps that were identified by the PACE panel
can guide further research on truncal acne.
Furthermore, the recommendations made can provide a basis for local guideline development and
help to improve the management of patients with
truncal acne by facilitating increased attention during
consultations.
Medical writing and administrative support were provided by Katie Harris, PhD, Ellie Hughes, PhD, James
Pickford, BSc, and Victoria Smith, BSc, at Ogilvy Health
UK.
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